Summary
- Between April 2019 and August 2021, 382 patients were screened, and 315 were eligible for the study, with 155 patients in each group receiving treatment.
- Patients had a median age of 59 years, with a majority having clinical stage IV disease, brain metastasis, and EGFR mutations.
- Gefitinib plus anlotinib significantly improved progression-free survival (PFS) compared to gefitinib plus placebo, especially in patients with EGFR mutations and brain metastasis.
- Dual therapy with gefitinib plus anlotinib reduced tumor mutational load and frequency of key driver gene mutations, potentially enhancing treatment efficacy.
- Safety analysis showed that treatment-related adverse events were common, with the most frequent being diarrhea, rash, and hypertension in the gefitinib plus anlotinib group, and rash and elevated liver enzymes in the gefitinib plus placebo group.
A recent study conducted between April 2019 and August 2021 has shown promising results for patients with advanced non-small cell lung cancer (NSCLC). The study involved 315 patients who were randomized to receive either gefitinib plus anlotinib or gefitinib plus placebo. The patients had a median age of 59 years, with 43.9% being male. Most patients had stage IV disease, with some having brain or liver metastasis.
The results of the study showed that the combination of gefitinib plus anlotinib significantly improved progression-free survival (PFS) compared to gefitinib plus placebo. Patients with certain genetic mutations, such as EGFR ex19del or ex21L858R, also showed better PFS with the combination therapy. Additionally, patients with brain metastasis had a longer PFS with gefitinib plus anlotinib compared to placebo.
The study also looked at the impact of the treatments on genetic mutations in the blood of the patients. Dual therapy with gefitinib plus anlotinib was found to reduce the tumor mutational load in patients at the time of disease progression. Moreover, the presence of certain genetic biomarkers, such as EGFR amplification, was associated with better outcomes with the combination therapy.
In terms of safety, the study found that treatment-emergent adverse events were more common in the group receiving gefitinib plus anlotinib, with side effects like diarrhea, rash, and hypertension being frequently reported. However, the combination therapy was generally well-tolerated, with manageable side effects.
Overall, the study provides hope for patients with advanced NSCLC, highlighting the potential benefits of combining gefitinib and anlotinib in improving outcomes. More research is needed to further explore the impact of these treatments on patient outcomes and genetic mutations associated with the disease.
Source link
Oncology,Pulmonary Medicine